Literature DB >> 23102590

Effects of immediate telephone follow-up with providers on sweat chloride test timing after cystic fibrosis newborn screening identifies a single mutation.

Alison La Pean1, Michael H Farrell, Kerry L Eskra, Philip M Farrell.   

Abstract

OBJECTIVE: To assess whether reporting "possible cystic fibrosis (CF)" newborn screening (NBS) results via fax plus simultaneous telephone contact with primary care providers (PCPs) versus fax alone influenced 3 outcomes: undergoing a sweat chloride test, age at sweat chloride testing, and undergoing sweat testing before age 8 weeks. STUDY
DESIGN: This was a retrospective cohort comparison of infants born in Wisconsin whose PCP received a telephone intervention (n = 301) versus recent historical controls whose PCP did not (n = 355). Intervention data were collected during a longitudinal research and quality improvement effort; deidentified comparison data were constructed from auxiliary NBS tracking information. Parametric and nonparametric statistical analyses were performed for group differences.
RESULTS: Most infants (92%) with "possible CF" NBS results whose PCP lacked telephone intervention ultimately underwent sweat testing, underlining efficacy for fax-only reporting. Telephone intervention was significantly associated with improvements in the infants undergoing sweat testing at age ≤6 weeks and <8 weeks and a slight, statistically nonsignificant 3.5-day reduction in the infants' age at sweat testing. The effect of telephone intervention was greater for PCPs whose patients underwent sweat testing at community-affiliated medical centers versus those whose patients did so at academic medical centers (P = .008).
CONCLUSION: Reporting "possible CF" NBS results via fax plus simultaneous telephone follow-up with PCPs increases the rate of sweat chloride testing before 8 weeks of age, when affected infants are more likely to receive full benefits of early diagnosis and treatment.
Copyright © 2013 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23102590      PMCID: PMC3582754          DOI: 10.1016/j.jpeds.2012.08.055

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  34 in total

1.  A decision-tree approach to cost comparison of newborn screening strategies for cystic fibrosis.

Authors:  Janelle Wells; Marjorie Rosenberg; Gary Hoffman; Michael Anstead; Philip M Farrell
Journal:  Pediatrics       Date:  2012-01-30       Impact factor: 7.124

2.  Psychological effects of false-positive results in cystic fibrosis newborn screening: a two-year follow-up.

Authors:  Julie Beucher; Emmanuelle Leray; Eric Deneuville; Monique Roblin; Isabelle Pin; François Bremont; Dominique Turck; Jean-Louis Giniès; Pascal Foucaud; Gilles Rault; Jocelyne Derelle; Valérie David; Hubert Journel; Sophie Marchand; David Veillard; Michel Roussey
Journal:  J Pediatr       Date:  2010-02-20       Impact factor: 4.406

3.  Sweat testing infants detected by cystic fibrosis newborn screening.

Authors:  Richard B Parad; Anne Marie Comeau; Henry L Dorkin; Mark Dovey; Robert Gerstle; Thomas Martin; Brian P O'Sullivan
Journal:  J Pediatr       Date:  2005-09       Impact factor: 4.406

Review 4.  An overview of international literature from cystic fibrosis registries 2. Neonatal screening and nutrition/growth.

Authors:  Donatello Salvatore; Roberto Buzzetti; Ermanno Baldo; Maria Pia Forneris; Vincenzina Lucidi; Daniela Manunza; Italo Marinelli; Barbara Messore; Anna Silvia Neri; Valeria Raia; Maria Lucia Furnari; Gianni Mastella
Journal:  J Cyst Fibros       Date:  2009-12-02       Impact factor: 5.482

5.  Predictors of insufficient sweat production during confirmatory testing for cystic fibrosis.

Authors:  Mary Kleyn; Steven Korzeniewski; Violanda Grigorescu; William Young; Douglas Homnick; Amy Goldstein-Filbrun; John Schuen; Samya Nasr
Journal:  Pediatr Pulmonol       Date:  2010-09-01

6.  Sweat-testing in preterm and full-term infants less than 6 weeks of age.

Authors:  Warren Eng; Vicky A LeGrys; Michael S Schechter; Matthew M Laughon; Pierre M Barker
Journal:  Pediatr Pulmonol       Date:  2005-07

7.  Parental understanding of newborn screening for cystic fibrosis after a negative sweat-test.

Authors:  Colleen Walsh Lang; Susanna A McColley; Lucille A Lester; Lainie Friedman Ross
Journal:  Pediatrics       Date:  2011-01-10       Impact factor: 7.124

8.  Optimal DNA tier for the IRT/DNA algorithm determined by CFTR mutation results over 14 years of newborn screening.

Authors:  Mei W Baker; Molly Groose; Gary Hoffman; Michael Rock; Hara Levy; Philip M Farrell
Journal:  J Cyst Fibros       Date:  2011-03-08       Impact factor: 5.482

9.  Nutritional status of infants with cystic fibrosis associated with early diagnosis and intervention.

Authors:  M S Marcus; S A Sondel; P M Farrell; A Laxova; P M Carey; R Langhough; E H Mischler
Journal:  Am J Clin Nutr       Date:  1991-09       Impact factor: 7.045

10.  Examination of the communication practices between state newborn screening programs and the medical home.

Authors:  Sunnah Kim; Michele A Lloyd-Puryear; Thomas F Tonniges
Journal:  Pediatrics       Date:  2003-02       Impact factor: 7.124

View more
  2 in total

1.  Improving newborn screening for cystic fibrosis using next-generation sequencing technology: a technical feasibility study.

Authors:  Mei W Baker; Anne E Atkins; Suzanne K Cordovado; Miyono Hendrix; Marie C Earley; Philip M Farrell
Journal:  Genet Med       Date:  2015-02-12       Impact factor: 8.822

2.  Newborn Screening Quality Assurance Program for CFTR Mutation Detection and Gene Sequencing to Identify Cystic Fibrosis.

Authors:  Miyono M Hendrix; Stephanie L Foster; Suzanne K Cordovado
Journal:  J Inborn Errors Metab Screen       Date:  2016-08-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.